ライフサイエンスコーパス: myosin light chain

1 ownstream effectors (phospholipase Cbeta and myosin light chain).

2 cells to injured cardiomyocytes (expressing myosin light chain.

3 in light chain phosphatase and subsequently, myosin light chain.

4 ting Rho kinase activity and phosphorylating myosin light chain.

5 including glycogen synthase kinase-3beta and myosin light chain.

6 um as judged by increased phosphorylation of myosin light chain.

7 he activation of RhoA and phosphorylation of myosin light chain.

8 Myosin light chain 1 (LC1) was labeled with a fluorescen

9 repression of troponin T3, troponin I2, and myosin light chain 1 between cardiac and slow-twitch ske

10 the actin-tropomyosin and myosin heavy chain-myosin light chain 1 interactions independently correlat

11 ns of OGA with alpha-actin, tropomyosin, and myosin light chain 1, along with reduced OGT and increas

12 itoylation of proteins involved in motility (myosin light chain 1, myosin A), cell morphology (PhIL1)

13 l muscle genes troponin T3, troponin I2, and myosin light chain 1.

14 ked actin-tropomyosin and myosin heavy chain-myosin light chain 1.

15 gin: including myofibrillar proteins (titin, myosin light chain 1/3, myomesin 3 and filamin-C), glyco

16 Species-specific peptides derived from myosin light chain-1 and 2 were identified for authentic

17 of troponin I, troponin T, phospholamban, or myosin light chain-1 or -2.

18 f Mstn selectively in skeletal muscle with a myosin light chain 1f (MLC1f)-cre allele induced robust

19 ly the phosphorylation of the ROCK substrate myosin light chain 2 (MLC2) in intact human breast, lung

20 for PKM2's localization and interaction with myosin light chain 2 (MLC2) in the contractile ring regi

21 rin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2).

22 Because phosphorylation of cardiac myosin light chain 2 (MLC2v), bound to myosin at the hea

23 ted kinase (ROCK) signaling concomitant with myosin light chain 2 and MYPT phosphorylation.

24 d pulmonary acetylcholine and phosphorylated myosin light chain 2 in bronchial smooth muscles.

25 myosin heavy chain, myosin light chain, and myosin light chain 2 phosphorylation, which showed no si

26 s whereas the phosphorylation of ventricular myosin light chain 2 was significantly increased, implyi

27 signaling and by the localization of phospho-myosin light chain 2, in turn controlling the changes in

28 xtracellular signal-regulated kinase, and/or myosin light chain 2.

29 with Rho kinase-dependent phosphorylation of myosin light chain 2.

30 iuretic peptide, beta-myosin heavy chain and myosin light chain (2- to 5-fold, P < 0.05).

31 decreased phosphorylation of the regulatory myosin light chain-2 (MLC2), a critical cytoskeletal reg

32 by myosin regulatory proteins (for example, myosin light chain-2 [MLC2]) in cardiac muscle remain po

33 osphorylation of several proteins, including myosin light chain-2 slow and troponin T and carbonylati

34 Since myosin light chain 20 (MLC(20)) phosphorylation appears

35 In addition, increased phosphorylation of myosin light chain-20, a key regulator of lymphatic musc

36 ssion of cardiac alpha-actinin, connexin 43, myosin light chain 2a, alpha/beta-myosin heavy chain, an

37 sion, evidenced by reduced expression of the myosin light chain 9 (MYL9) component of myosin II compl

38 Independent of the myosin light chain activation, RHGF-1 acted through Rho-

39 ion, which prevents dephosphorylation of the myosin light chain, allowing actomyosin contractility to

40 increased levels of F-actin, phosphorylated myosin light chain, alpha-smooth muscle actin, collagen-

41 y, which is necessary for phosphorylation of myosin light chain and actin myosin-mediated contraction

42 wever, the structural features of this novel myosin light chain and its interaction with its cognate

43 activity to downstream effectors, including myosin light chain and p38(MAPK), and is reversed upon t

44 by means of reducing the phosphorylation of myosin light chain and vascular endothelial (VE)-cadheri

45 evidence, complexes between CaM or CaM-like myosin light chains and IQ motifs are highly diverse and

46 he myofilament proteins, myosin heavy chain, myosin light chains and subunits of the Troponin complex

47 ion and elevated active RhoA, phosphorylated myosin light chain, and F-actin accumulation.

48 d a detailed analysis of myosin heavy chain, myosin light chain, and myosin light chain 2 phosphoryla

49 Myosin light chains are key regulators of class 1 myosin

50 Pm and Azi-iso identified myosin, actin, and myosin light chain as targets of the anesthetics.

51 hereas F-actin, vinculin, and phosphorylated myosin light chain associated only with the peripheral a

52 Thr853 (pT853), CPI-17 at Thr38 (pT38), and myosin light chain at Ser19 (pS19).

53 ronger and more sustained phosphorylation of myosin light chain at serine 19 and threonine 18.

54 ion resulted in decreased phosphorylation of myosin light chains, attenuated smooth muscle contractil

55 A single lobe light chain, myosin light chain C (MlcC), was recently identified and

56 adjacent to the MTIP-binding site, and both myosin light chains co-located to the glideosome.

57 Phosphorylated myosin light chain colocalization with actin stress fibe

58 e, the complex included GAP40, an additional myosin light chain designated essential light chain (ELC

59 erall morphology, f-actin and phosphorylated myosin light chain distribution, and nuclear position an

60 Apically, in the absence of CFL1 myosin light chain does not become phosphorylated, indic

61 structure of a phosphorylated smooth-muscle myosin light chain domain (LCD).

62 the 2.3-A-resolution crystal structure of a myosin light chain domain, corresponding to one type fou

63 e with the force-transducing rotation of the myosin light-chain domain.

64 ble-green-fluorescent-protein (PAGFP)-tagged myosin light chain expressed in zebrafish skeletal muscl

65 s p.Glu11Lys mutation in the atrial-specific myosin light chain gene MYL4.

66 alpha-smooth muscle actin and phosphorylated myosin light chain in cortical patches, decreased abunda

67 Interestingly, tropomyosin and myosin light chains in comminuted sausages were exclusiv

68 Those same doses of CXCL12 locked myosin light chain into a phosphorylated state, thereby

69 -actin and myosin accumulate and the ectopic myosin light chain is phosphorylated.

70 site to 0.45 mol of phosphate/mol by cardiac myosin light chain kinase (cMLCK) increases Ca(2+) sensi

71 he well-known, muscle-specific smooth muscle myosin light chain kinase (MLCK) (smMLCK) and skeletal m

72 uce barrier defects that are associated with myosin light chain kinase (MLCK) activation and increase

73 actor (alpha) (TNF) signaling and epithelial myosin light chain kinase (MLCK) activation.

74 dominantly by Rho kinase in both cell types, myosin light chain kinase (MLCK) also appeared to contro

75 on of myosin regulatory light chain (RLC) by myosin light chain kinase (MLCK) and myosin binding prot

76 thway involving the MAP kinases MEK and ERK, myosin light chain kinase (MLCK) and Myosin IIB.

77 ve activities of Ca(2+)-calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

78 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase (MLCK) and myosin light chain

79 in (RLC) phosphorylation, which is driven by myosin light chain kinase (MLCK) and Rho-associated kina

80 Here we have identified myosin light chain kinase (MLCK) as a regulator of membr

81 Inhibition of myosin light chain kinase (MLCK) blocked the effects of

82 ion phenotype was primarily due to increased myosin light chain kinase (MLCK) expression.

83 transgenic mice expressing calmodulin sensor myosin light chain kinase (MLCK) in smooth muscles, the

84 mplex (ARPC) subunit 2, 3, and 5, as well as myosin light chain kinase (MLCK) in these cells.

85 ocusing on regulatory roles of IFN-gamma and myosin light chain kinase (MLCK) in TW myosin phosphoryl

86 d in the absence or presence of the specific myosin light chain kinase (MLCK) inhibitor ML-7 under bo

87 ABSTRACT: Ca(2+) /calmodulin activation of myosin light chain kinase (MLCK) initiates myosin regula

88 Ca(2+)/calmodulin-dependent myosin light chain kinase (MLCK) phosphorylates smooth m

89 Herein, we show that myosin light chain kinase (MLCK) plays a central role in

90 , where it bound to its binding motif on the myosin light chain kinase (MLCK) promoter region, leadin

91 ulin-dependent protein kinase II (CaMKII) to myosin light chain kinase (MLCK) to myosin light chain,

92 myosin II, Rho-associated kinase (ROCK), and myosin light chain kinase (MLCK) were also recruited to

93 ted by arp2/3 and contractility regulated by myosin light chain kinase (MLCK) were responsible for th

94 The mylk1 gene encodes a 220-kDa nonmuscle myosin light chain kinase (MLCK), a 130-kDa smooth muscl

95 iated response that leads to upregulation of myosin light chain kinase (MLCK), a hallmark of the path

96 reduction in the expression and activity of myosin light chain kinase (MLCK), a primary regulator of

97 lity pathway involving Rho kinase (ROCK) and myosin light chain kinase (MLCK), culminating in the act

98 Myosin light chain kinase (MLCK)-dependent phosphorylati

99 erijunctional actomyosin ring contributes to myosin light chain kinase (MLCK)-dependent tight junctio

100 We showed previously that a myosin light chain kinase (MLCK)-myosin II pathway was r

101 ad spectrum of downstream targets, including myosin light chain kinase (MLCK).

102 ght junction (TJ) permeability by activating myosin light chain kinase (MLCK; official name MYLK3) ge

103 The authors investigated the role of myosin light chain kinase (MYLK) and transforming growth

104 sequencing, we found homozygous variants in myosin light chain kinase (MYLK) in both families.

105 d by TRPC6, in turn, activates the nonmuscle myosin light chain kinase (MYLK), which not only increas

106 Nonmuscle myosin light chain kinase (nmMLCK), a multi-functional c

107 nied by an increase in protein expression of myosin light chain kinase (P<0.05) and casein kinase II-

108 Smooth muscle myosin light chain kinase (SM-MLCK) is the key enzyme re

109 Smooth muscle myosin light chain kinase (smMLCK) is a calcium-calmodul

110 Smooth muscle myosin light chain kinase (smMLCK) is a member of a dive

111 ene that encodes nonmuscle and smooth muscle myosin light chain kinase (smMLCK) isoforms and regulate

112 nase that controls SMC contractile function (myosin light chain kinase [MYLK]) cause FTAAD, we sequen

113 In turn, IL-1beta increased NF-kappaB and myosin light chain kinase activation in intestinal epith

114 endent myosin light chain phosphorylation by myosin light chain kinase and actin stress fiber formati

115 osphorylated by Ca(2+) /calmodulin-dependent myosin light chain kinase and dephosphorylated by myosin

116 development in ileal smooth muscle depend on myosin light chain kinase and MLCP activities without ch

117 e activities of Ca(2+) /calmodulin-dependent myosin light chain kinase and myosin light chain phospha

118 Myosin light chain kinase and phosphatase activities are

119 Both myosin light chain kinase and Rho-associated kinase acte

120 lated through two myosin-signaling pathways, myosin light chain kinase and Rho-associated kinase.

121 lated these recombinant species with cardiac myosin light chain kinase and zipper-interacting protein

122 measuring the stabilization of calmodulin by myosin light chain kinase at dramatically higher unfoldi

123 Blocking beta1-integrin, Src, ERK, or myosin light chain kinase by short hairpin RNA or pharma

124 Intestinal myosin light chain kinase expression decreased in Cd14-d

125 lly expressed gene (Speg) is a member of the myosin light chain kinase family.

126 MEKK-1 also played an essential role in myosin light chain kinase gene activation.

127 osphorylated by a dedicated Ca(2+)-dependent myosin light chain kinase in fast skeletal muscle, where

128 Concordantly, treatment of cells with the myosin light chain kinase inhibitor ML-7 or the myosin I

129 inant negative mutant RhoA(T19N) and Rho and myosin light chain kinase inhibitors.

130 A Ca(2+)/calmodulin-activated myosin light chain kinase is expressed only in cardiac m

131 he recent identification of cardiac-specific myosin light chain kinase necessary for basal RLC phosph

132 ression of contraction through inhibition of myosin light chain kinase normalized the effects of subs

133 ented cytoskeletal defects, while inhibiting myosin light chain kinase or phosphorylation of focal ad

134 hidden and unphosphorylated; on activation, myosin light chain kinase phosphorylates the monophospho

135 inal extension (Dmlc2(Delta2-46)), disrupted myosin light chain kinase phosphorylation sites (Dmlc2(S

136 We tested the functionality of myosin light chain kinase pseudogene (MYLKP1) in human c

137 rough RhoA GTPase, Rho-associated kinase, or myosin light chain kinase restored stiffness-dependent s

138 Phosphorylation of myosin-bound RLC by myosin light chain kinase substantially inhibits binding

139 m1a), expressed specifically in the MHB, and myosin light chain kinase together mediate MHBC cell len

140 ntraction with isoproterenol, or by blocking myosin light chain kinase with ML-7.

141 nhibition of actin polymerization as well as myosin light chain kinase with the drug ML7 limited both

142 RT-PCR analysis of tight junction proteins, myosin light chain kinase, and proinflammatory cytokine

143 density and progressed independently of Rac, myosin light chain kinase, and Rho kinase, suggesting a

144 including methionine sulfoxide reductase A, myosin light chain kinase, and Runt-related transcriptio

145 in action, including Mal2, Akap12, gelsolin, myosin light chain kinase, annexin-2, and Hsp70, manifes

146 in), regulators of the contractile response (myosin light chain kinase, myosin phosphatase target sub

147 ytosis, and localized phosphorylation of the myosin light chain kinase, thereby impinging on the acto

148 titutively active mutants of RhoA GTPase and myosin light chain kinase, we show that varying the expr

149 Upon photodisruption and recoil, myosin light chain kinase-dependent SFs located along th

150 at neutrophil transmigration is regulated by myosin light chain kinase-mediated endothelial cell cont

151 ion development at the leading edge requires myosin light chain kinase-mediated myosin II contractili

152 )) at Ser(19) by Ca(2+)/calmodulin-dependent myosin light chain kinase.

153 mplitude and partly by a mechanism involving myosin light chain kinase.

154 sphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(s) playe

155 Myosin light-chain kinase (MLCK) is a downstream target

156 egulated the downstream nuclear factor-B and myosin light-chain kinase (MLCK) signalling, and these c

157 Nonmuscle myosin light-chain kinase (nmMLCK), the predominant MLCK

158 mbers, we demonstrated the role of nonmuscle myosin light-chain kinase (nmMYLK) in Tat(1)(-)(7)(2) (1

159 contraction of actin filaments by activating myosin light-chain kinase and myosin II behind the leadi

160 Nonmuscle myosin light-chain kinase contributes to atherosclerosis

161 n of myosin phosphatase or inhibition of the myosin light-chain kinase in nonmalignant cells could re

162 ression of myosin phosphatase and/or reduced myosin light-chain kinase levels.

163 Here we identify a myosin light-chain kinase MRCK-1 as a key regulator of C

164 s, including phosphatidylinositol 3-kinases, myosin light-chain kinase, Ras-related C3 botulinum toxi

165 um channels and calcium/calmodulin-dependent myosin light-chain kinase.

166 in II heavy chain (MHC) and the long form of myosin light-chain kinase.

167 M, cytochalasin D, and inhibitors of Rho and myosin light chain kinases blocked both responses.

168 Here, we show that deletion of myosin light-chain kinases (MLCK) in the smooth muscle c

169 yosin phosphatase (MP) is a key regulator of myosin light chain (LC20) phosphorylation, a process ess

170 yosins that lack a tail region, the atypical myosin light chains may fulfill that role.

171 IPF, using phosphorylation of the regulatory myosin light chain (MLC(20)) as a biomarker of in vivo c

172 2 demonstrates no requirement for regulatory myosin light chain (MLC(20)) phosphorylation for maximum

173 nd CXCR4, and inhibited Ca(2+) mobilization, myosin light chain (MLC) 2 phosphorylation, and contract

174 ), which modifies the activity of regulatory myosin light chain (MLC) and cofilin by altering their p

175 ive manner and suppressed phosphorylation of myosin light chain (MLC) and CPI-17, but not myosin targ

176 phosphorylation of intracellular epithelial myosin light chain (MLC) and screened using Caco-2 monol

177 we demonstrate that the non-muscle ~214-kDa myosin light chain (MLC) kinase (nmMLCK) modulates the i

178 part, to a Ca(2+)-independent activation of myosin light chain (MLC) phosphatase by protein kinase G

179 Myosin light chain (MLC) phosphorylation and MLC kinase

180 Platelet myosin light chain (MLC) phosphorylation and transcript

181 Time- and dose-dependent myosin light chain (MLC) phosphorylation in response to

182 increased smooth muscle stress and decreased myosin light chain (MLC) phosphorylation in vivo, provid

183 of MRP4 expression on cAMP and cGMP levels, myosin light chain (MLC) phosphorylation, actin filament

184 nges in gene expression, actin cytoskeleton, myosin light chain (MLC) phosphorylation, and extracellu

185 Barrier function, MAPk and myosin light chain (MLC) phosphorylation, tight junction

186 gonist-evoked intracellular calcium flux and myosin light chain (MLC) phosphorylation, which are prer

187 ell (VSMC) tone is regulated by the state of myosin light chain (MLC) phosphorylation, which is in tu

188 ROCK inhibition increased myosin light chain (MLC) phosphorylation, which is known

189 A myosin light chain (MLC) tagged with photoactivatable gr

190 mulus requires phosphorylation of the 20 kDa myosin light chain (MLC), which activates crossbridge cy

191 RhoA-bound ROCK1 phosphorylates myosin light chain (MLC), which is required for actin-my

192 hat Git2a is required for phosphorylation of myosin light chain (MLC), which regulates myosin II-medi

193 ough their effects on the phosphorylation of myosin light chain (MLC).

194 accompanied by diminished phosphorylation of myosin light chain (MLC).

195 pended on the phosphorylation of endothelial myosin light chain (MLC).

196 ed using FRET probes, and phosphorylation of myosin light chain (MLC-p), a downstream target of RhoA,

197 r calcium ([Ca(2+)]i) and phosphorylation of myosin light chains (MLC).

198 hoA and RhoC activity, which in turn affects myosin light-chain (MLC) phosphorylation.

199 esponsible for phosphorylation of regulatory myosin light chain (MLC20), resulting in actin-myosin cr

200 n several cytoskeletal/contractile proteins (myosin light chain MLY2, myosin heavy chain 6, myosin-bi

201 increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representati

202 target subunit (MYPT1) and the expression of myosin light chain of myosin II (MLC2), which was identi

203 d RhoA/Rho kinase-induced phosphorylation of myosin light chain on Ser19.

204 et subunit of myosin phosphatase with either myosin light chain or HDAC6, a microtubule deacetylase.

205 ssociated with changes in phosphorylation of myosin light chain or of myosin light chain phosphatase

206 t analysis was used to measure the extent of myosin light chain (p-MLC) phosphorylation and ratio of

207 bsequent dephosphorylation for relaxation by myosin light chain phosphatase (MLCP) containing regulat

208 ctivation, force and phosphorylation of RLC, myosin light chain phosphatase (MLCP) targeting subunit

209 ulin-dependent myosin light chain kinase and myosin light chain phosphatase (MLCP), which contains a

210 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

211 ed form of myosin-binding subunit (P-MBS) of myosin light chain phosphatase (MLCP).

212 n light chain kinase and dephosphorylated by myosin light chain phosphatase (MLCP).

213 pendent myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP).

214 l of phosphate/mol of RLC with inhibition of myosin light chain phosphatase (MLCP).

215 CPI-17, but not myosin targeting subunit of myosin light chain phosphatase (MYPT1).

216 ads to down-regulation of smooth muscle (SM) myosin light chain phosphatase activity, an increase in

217 Ca(2+) sensitivity usually is attributed to myosin light chain phosphatase activity, but findings in

218 the Rho signaling pathway and inhibition of myosin light chain phosphatase activity.

219 t phosphorylation of LC20 upon inhibition of myosin light chain phosphatase activity.

220 lated, phosphorylation of the ROCK substrate myosin light chain phosphatase and subsequently, myosin

221 through RhoA/ROCK-mediated inhibition of the myosin light chain phosphatase complex (MLCP).

222 unts of free Ca(2+)/calmodulin combined with myosin light chain phosphatase inhibition is sufficient

223 Inhibition of myosin light chain phosphatase leads to Ca(2+)-independe

224 nist-induced contractile force, RLC(20), and myosin light chain phosphatase phosphorylation in both i

225 Phosphorylation of two myosin light chain phosphatase regulatory proteins (MYPT

226 Phosphorylation of the myosin light chain phosphatase regulatory subunit MYPT1

227 phosphorylation of myosin light chain or of myosin light chain phosphatase regulatory subunit.

228 by a GST-MYPT1(654-880) fragment inhibiting myosin light chain phosphatase were antagonized by the a

229 endogenous MYPT1 (the regulatory subunit of myosin light chain phosphatase) at Thr-696/Thr-853 or ac

230 hibitory protein of 17 kDa (CPI-17) inhibits myosin light chain phosphatase, altering the levels of m

231 This occurs through inhibition of myosin light chain phosphatase, leading to increased pho

232 eral different downstream substrates such as myosin light chain phosphatase, LIM kinase and ezrin/rad

233 selectively inhibits a specific form of PP1, myosin light chain phosphatase, which transduces multipl

234 vesicle biogenesis through the regulation of myosin light chain phosphatase.

235 The small phosphoprotein pCPI-17 inhibits myosin light-chain phosphatase (MLCP).

236 and/or the leucine zipper (LZ) domain of the myosin light-chain phosphatase component, myosin-binding

237 lex and allow reevaluation of the role(s) of myosin light-chain phosphatase partner polypeptides in r

238 etion of either RhoC or MRK causes sustained myosin light chain phosphorylation after LPA stimulation

239 he RhoA/Rho kinase pathway via inhibition of myosin light chain phosphorylation and actin depolymeriz

240 Force development, but not myosin light chain phosphorylation and actin polymerizat

241 ht chain phosphatase, altering the levels of myosin light chain phosphorylation and Ca(2+) sensitivit

242 s of connexin-50, together with decreases in myosin light chain phosphorylation and the levels of 14-

243 cells was accompanied by RhoA activation and myosin light chain phosphorylation and was reduced by th

244 RhoA activity and myosin light chain phosphorylation are elevated in GRAF3

245 Nevertheless, myosin light chain phosphorylation at Ser-19 and actin p

246 smooth muscle contraction without affecting myosin light chain phosphorylation at Ser-19.

247 ular signal-regulated kinase (ERK)-dependent myosin light chain phosphorylation by myosin light chain

248 increased migration was associated with high myosin light chain phosphorylation by PI3K/ERK-dependent

249 active Rho, localization of both RhoGTP and myosin light chain phosphorylation corresponds to Myo9b-

250 ractility, RhoA activation, and constitutive myosin light chain phosphorylation ex vivo compared with

251 ther, overexpression of HIF-1alpha decreased myosin light chain phosphorylation in HIF-1alpha-null SM

252 se of RhoA activity accompanied by augmented myosin light chain phosphorylation in mesenteric arterie

253 diminished Ca(2+)-independent and -dependent myosin light chain phosphorylation otherwise increased b

254 ellular calcium measurements, and regulatory myosin light chain phosphorylation status.

255 Increased myosin light chain phosphorylation suggested that noncan

256 ugh the ROCK isoforms both regulate MLCP and myosin light chain phosphorylation through different mec

257 ay activates phospholipase Cbeta and induces myosin light chain phosphorylation to enhance actomyosin

258 ng experiments, we show that CD11b modulates myosin light chain phosphorylation to suppress lateral p

259 However, myosin light chain phosphorylation was not affected by T

260 Moreover, myosin light chain phosphorylation, a determinant of SMC

261 is required for cell spreading on collagen, myosin light chain phosphorylation, and focal adhesion m

262 Enhanced TW myosin light chain phosphorylation, arc formation, and b

263 companied by inhibition of RhoA activity and myosin light chain phosphorylation, as well as decreased

264 n polymerization; however, it did not affect myosin light chain phosphorylation, which is necessary f

265 lcium, and decreased actin stress fibers and myosin light chain phosphorylation, without detectable c

266 tudies showed that nmMLCK acted through both myosin light chain phosphorylation-coupled and -uncouple

267 ion, activation of MRK causes a reduction in myosin light chain phosphorylation.

268 uction driven by stronger and more sustained myosin light chain phosphorylation.

269 ns low pulmonary vascular tone by decreasing myosin light chain phosphorylation.

270 ast, as expected, depletion of RhoA inhibits myosin light chain phosphorylation.

271 caused a decrease in actin stress fibers and myosin light chain phosphorylation.

272 he effect of Efnb1 on VSMC contractility and myosin light chain phosphorylation.

273 apical nonmuscle myosin II accumulation and myosin light chain phosphorylation.

274 P, yet both ROCK isoforms regulated MLCP and myosin light chain phosphorylation.

275 due to alterations in calcium homeostasis or myosin light chain phosphorylation.

276 phosphorylation at Ser-56 without affecting myosin light chain phosphorylation.

277 lowing cholinergic stimulation and increased myosin light chain phosphorylation.

278 on in response to ACh, but it did not affect myosin light chain phosphorylation.

279 oA, reduced RhoA GTP-loading and reversal of myosin light chain phosphorylation.

280 1.38 +/- 0.072-fold (mean+/-SE) increase in myosin light-chain phosphorylation 48 h post-treatment,

281 PPAP2B inhibition resulted in myosin light-chain phosphorylation and intercellular gap

282 hat the Net1A isoform predominantly controls myosin light-chain phosphorylation and is required for t

283 ding via downregulation of RhoA activity and myosin light-chain phosphorylation and triggered F-actin

284 n program that eventually leads to decreased myosin light-chain phosphorylation and, thus, decreased

285 When myosin light-chain phosphorylation was restored to norma

286 ivity via decreased intestinal smooth muscle myosin light-chain phosphorylation, leading to slower in

287 n also attenuated edema-induced decreases in myosin light-chain phosphorylation.

288 pha inhibited Myosin II motors by decreasing Myosin light-chain phosphorylation.

289 nuclear reprogramming of the muscle-specific myosin light chain promoter did occur.

290 raction force microscopy, and phosphorylated myosin light chain quantity and actin fiber colocalizati

291 uired for fusion as the expression of mutant myosin light chain reduced membrane fusion.

292 Contractile components (SM-actin and myosin light chain), regulators of the contractile respo

293 t chain phosphatase activity, an increase in myosin light chain (RLC(20)) phosphorylation and force.

294 , invertebrate tropomyosin, arginine kinase, myosin light chain, sarcoplasmic calcium-binding protein

295 m microtubules to initiate a RhoA/Rho kinase/myosin light chain signaling pathway that regulates cell

296 One mutation affects Cdc4, a myosin light chain that is an essential component of the

297 MKII) to myosin light chain kinase (MLCK) to myosin light chain, the last of which controls the contr

298 Both filamentous actin and phosphorylated myosin light chain were enriched at the apical surface o

299 ted contraction (via ROCK phosphorylation of myosin light chain), which are coupled to ECM signaling

300 f Rho kinase activity and phosphorylation of myosin light chain, which induces airway smooth muscle c